Albumin-bound Paclitaxel Combined With Gemcitabine First-line Inoperable Pancreatic Cancer
Status:
Recruiting
Trial end date:
2026-12-01
Target enrollment:
Participant gender:
Summary
This study aims to further observe and evaluate whether the three-week administration of
albumin-bound paclitaxel combined with gemcitabine is equivalent to the four-week
administration in the treatment of inoperable locally advanced or metastatic pancreatic
cancer
Phase:
Phase 4
Details
Lead Sponsor:
Tianjin Medical University Cancer Institute and Hospital